Jimmy Weterings, PhDPrincipal Scientist, Oligonucleotide Chemistry at AstraZeneca
Profile
Jimmy Weterings is Principal Scientist in the Discovery Sciences – Oligonucleotide chemistry team at AstraZeneca.
Jimmy has had a tight bond with Oligonucleotides since 2002, performing research on PNA in the van Boom group at Leiden University and targeted ASO conjugates at Prosensa. During his Ph.D at Leiden University he synthesised and studied CpG and other TLR ligand containing conjugates. At Cenix BioScience, he developed targeted siRNA conjugates for CNS delivery. And at Cristal Therapeutics he lead various projects on the nanomedicine delivery of oligonucleotide in oncology. Recently he joined AstraZeneca, fully dedicating himself to the further advancement of (targeted) oligonucleotide therapeutics.
Jimmy (co-)authored 11 articles and holds several patents for drug delivery enabling technologies, including the most recent one on TMTHSI, a promising new conjugation compound for oligonucleotide and antibody conjugates.
Agenda Sessions
Oligonucleotide Conjugation Strategies
12:15View SessionSESSION NAME: Oligonucleotide Conjugation Strategies SESSION CHAIR:
On DemandView SessionSESSION NAME: Oligonucleotide Conjugation Strategies SESSION CHAIRS & SPEAKERS BELOW:
On DemandView SessionThe Art of Making Oligonucleotide Conjugates
On DemandView SessionThe Art of making Oligonucleotide Conjugates
On DemandView Session